(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 248.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Roivant Sciences's revenue in 2025 is $20,329,000.On average, 12 Wall Street analysts forecast ROIV's revenue for 2026 to be $13,292,931,237, with the lowest ROIV revenue forecast at $6,134,236,044, and the highest ROIV revenue forecast at $24,829,050,656. On average, 12 Wall Street analysts forecast ROIV's revenue for 2027 to be $111,848,961,524, with the lowest ROIV revenue forecast at $12,541,104,802, and the highest ROIV revenue forecast at $340,401,416,046.
In 2028, ROIV is forecast to generate $704,533,005,995 in revenue, with the lowest revenue forecast at $329,496,107,522 and the highest revenue forecast at $1,325,607,018,190.